Ramsay Health Care Ltd (ASX: RHC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Ramsay Health Care Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Ramsay Health Care Ltd (ASX: RHC)
Latest News

Broker Notes
UBS warns of more downgrades for ASX 200 shares… but not all

Healthcare Shares
Why is the Ramsay share price smashing the ASX 200 on Monday?

Healthcare Shares
Ramsay Health Care share price on watch amid Bupa contract termination

Share Gainers
These were the best performing ASX 200 shares in April

Share Market News
ASX 200 midday update: ResMed disappoints, PointsBet rockets higher

Earnings Results
Ramsay Health share price bleeds as profits plunge

Share Gainers
These were the best performing ASX 200 shares last week

Share Market News
Here are the top 10 ASX shares today
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
07 Mar 2022 | $0.4850 | 100.00% | Interim | 31 Mar 2022 |
06 Sep 2021 | $1.0300 | 100.00% | Final | 30 Sep 2021 |
08 Mar 2021 | $0.4850 | 100.00% | Interim | 31 Mar 2021 |
05 Mar 2020 | $0.6250 | 100.00% | Interim | 27 Mar 2020 |
05 Sep 2019 | $0.9150 | 100.00% | Final | 30 Sep 2019 |
06 Mar 2019 | $0.6000 | 100.00% | Interim | 29 Mar 2019 |
05 Sep 2018 | $0.8650 | 100.00% | Final | 28 Sep 2018 |
06 Mar 2018 | $0.5750 | 100.00% | Interim | 29 Mar 2018 |
05 Sep 2017 | $0.8150 | 100.00% | Final | 28 Sep 2017 |
07 Mar 2017 | $0.5300 | 100.00% | Interim | 29 Mar 2017 |
06 Sep 2016 | $0.7200 | 100.00% | Final | 29 Sep 2016 |
08 Mar 2016 | $0.4700 | 100.00% | Interim | 30 Mar 2016 |
04 Sep 2015 | $0.6050 | 100.00% | 24 Sep 2015 | |
05 Mar 2015 | $0.4050 | 100.00% | 26 Mar 2015 | |
08 Sep 2014 | $0.5100 | 100.00% | Final | 24 Sep 2014 |
04 Mar 2014 | $0.3400 | 100.00% | Interim | 26 Mar 2014 |
03 Sep 2013 | $0.4150 | 100.00% | Final | 25 Sep 2013 |
04 Mar 2013 | $0.2900 | 100.00% | Interim | 27 Mar 2013 |
05 Mar 2012 | $0.2550 | 100.00% | Interim | 28 Mar 2012 |
02 Sep 2011 | $0.2950 | 100.00% | Final | 26 Sep 2011 |
08 Mar 2011 | $0.2250 | 100.00% | Interim | 28 Mar 2011 |
31 Aug 2010 | $0.2500 | 100.00% | Final | 27 Sep 2010 |
16 Mar 2010 | $0.1850 | 100.00% | Interim | 09 Apr 2010 |
21 Sep 2009 | $0.2150 | 100.00% | Final | 09 Oct 2009 |
20 Mar 2009 | $0.1650 | 100.00% | Interim | 08 Apr 2009 |
RHC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Ramsay Health Care Ltd
Ramsay Health Care Limited (RHC) is a global healthcare company that operates 221 hospitals and 14 day surgery centres, treatment facilities, rehabilitation and psychiatric units and a nursing college across Australia, United Kingdom, France, Indonesia, Malaysia and Italy.
Established in Sydney, Australia, in 1964, Ramsay Health Care has more than 50 years of experience in providing acute health care services. RHC made its ASX debut in 1997 and the Ramsay share price has gone from strength to strength since.
Today, Ramsay employs more than 77,000 staff and delivers a range of acute and primary healthcare services from 480 facilities across 11 countries, making it one of the largest and most diverse private healthcare companies in the world.
RHC Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
04 Jul 2022 | $72.67 | $-0.33 | -0.45% | 389,810 | $74.49 | $74.67 | $72.67 |
01 Jul 2022 | $73.00 | $-0.24 | -0.33% | 383,859 | $73.32 | $74.16 | $73.00 |
30 Jun 2022 | $73.24 | $0.00 | 0.00% | 474,688 | $73.18 | $73.79 | $72.99 |
29 Jun 2022 | $73.24 | $-0.31 | -0.42% | 535,185 | $72.04 | $73.62 | $72.04 |
28 Jun 2022 | $73.55 | $-0.09 | -0.12% | 326,361 | $74.00 | $74.00 | $73.19 |
27 Jun 2022 | $73.64 | $2.12 | 2.96% | 271,674 | $71.80 | $73.99 | $71.80 |
24 Jun 2022 | $71.52 | $0.39 | 0.55% | 516,694 | $71.10 | $71.52 | $69.93 |
23 Jun 2022 | $71.13 | $-0.14 | -0.20% | 405,736 | $72.14 | $72.14 | $70.95 |
22 Jun 2022 | $71.27 | $-0.26 | -0.36% | 394,120 | $71.57 | $72.52 | $71.21 |
21 Jun 2022 | $71.53 | $0.12 | 0.17% | 417,016 | $71.42 | $72.07 | $71.07 |
20 Jun 2022 | $71.41 | $0.60 | 0.85% | 647,058 | $70.95 | $71.75 | $70.46 |
17 Jun 2022 | $70.81 | $-2.32 | -3.17% | 1,287,772 | $72.24 | $72.56 | $70.69 |
16 Jun 2022 | $73.13 | $-1.01 | -1.36% | 825,893 | $75.40 | $75.40 | $72.74 |
15 Jun 2022 | $74.14 | $-0.64 | -0.86% | 814,461 | $75.00 | $75.20 | $73.71 |
14 Jun 2022 | $74.78 | $-2.69 | -3.47% | 859,050 | $75.00 | $75.36 | $73.83 |
10 Jun 2022 | $77.47 | $0.00 | 0.00% | 561,394 | $77.64 | $78.04 | $77.42 |
09 Jun 2022 | $77.47 | $0.49 | 0.64% | 783,092 | $77.86 | $78.25 | $77.27 |
08 Jun 2022 | $76.98 | $1.21 | 1.60% | 431,577 | $75.64 | $77.37 | $75.57 |
07 Jun 2022 | $75.77 | $-1.02 | -1.33% | 465,938 | $76.13 | $76.55 | $75.23 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
29 Apr 2022 | Karen Penrose | Exercise | 580 | $39,996 |
Conversion of securities.
|
29 Apr 2022 | Karen Penrose | Issued | 580 | $39,996 |
Conversion of securities. average price, VWAP
|
15 Dec 2021 | Craig McNally | Issued | 57 | $3,951,765 |
Issue of securities. 163,736 - Performance Rights
|
03 Sep 2021 | Karen Penrose | Issued | 580 | $39,996 |
Employee Share Ownership Plan/Directors Salary Sacrifice. 580 - Share Rights
Average price/VWAP |
31 Aug 2021 | Craig McNally | Expiry | 90 | $6,223,392 |
As advised by the company. 106,046 - Performance Rights
90,325 Performance Rights granted under the Executive Performance Rights Plan failed to vest and therefore lapsed on 31 August 2021. |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Peter John Evans | Non-Executive DirectorNon-Executive Deputy Chairman | Dec 1990 |
Mr Evans began working with Ramsay Health Care in 1969. He is a Chartered Accountant who was in public practice for over 20 years with predecessor firms of KPMG. Mr Evans has specialised in the financial management of hospitals and has had experience in the health care field for 50 years. Mr Evans is also a Trustee of the Paul Ramsay Foundation. He is Chair of the Risk committee.
|
Mr David Ingle Thodey | Non-Executive Director | Nov 2017 |
Mr Thodey is a business leader who has had a executive career in the technology and telecommunications industries, with more than 30 years of experience creating brand and shareholder value. In addition to being a Non-Executive Director and Lead Independent Director of Ramsay Health Care, Mr Thodey is currently Chairman of Australia's national scientific research agency, the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Chairman of Tyro Payments Limited (a leading alternative payments provider) and Xero Limited (a small business accounting software company). Mr Thodey also had a successful career as CEO of Telstra, Australia's leading telecommunications and information services company, and prior to that he was CEO of IBM. Mr Thodey was awarded an Order of Australia in 2017 for his service to business and the promotion of ethical leadership and workplace diversity. In the past three years, Mr Thodey has served as a Director of the following listed companies: Xero Limited (Appointed June 2019), Tyro Payments Limited (Appointed November 2018) and Vodafone Group Plc (Resigned July 2020). He is chairman of Governance Committee and member of People Committee.
|
Ms Catriona Alison Deans | Non-Executive Director | Nov 2018 |
Ms Deans has 25 years of experience building technology-enabled businesses involved in media, ecommerce, financial services and health, and across leadership roles as an executive, a director and in venture capital. She is also Chair of Cochlear Limited and a Non-Executive Director of SCEGGS Darlinghurst and Deputy Pty Ltd. She is also on the Investment Committee of MainSequence Ventures.
In her executive career, Ms Deans was previously the CEO of eBay Australia and New Zealand, CEO of eCorp Limited, (a publicly listed portfolio of digital businesses), CEO of Hoyts Cinemas and, most recently, CEO of netus Pty Ltd - a technology investment company acquired by Fairfax. Ms Deans also spent seven years as a Consultant with McKinsey & Company and is currently a Senior Advisor with the firm. She is chair of the people committee. |
Mr Michael Stanley Siddle | Non-Executive DirectorNon-Executive Chairman | May 1975 |
Mr Siddle has experience in the management of private hospitals and has been integrally involved in Ramsay Health Care's successful expansion through construction, mergers and acquisitions. He is also a Director of the Paul Ramsay Foundation He is a member of the People and Governance committee.
|
Mr Craig Ralph McNally | Chief Executive OfficerManaging Director | Jul 2017 |
Mr McNally has worked across operational, strategic and financial roles. Mr McNally is also the Chairman of Ramsay Sante.
|
Ms Karen Lee Collett Penrose | Non-Executive Director | Mar 2020 |
Ms Penrose has had an executive career in leadership and CFO roles, mainly in financial services. She has worked in financial management, customer outcomes and operating in a rapidly changing regulatory environment which stems from 20 years in banking with Commonwealth Bank and HSBC and eight years as a listed-company CFO. In addition to being a Non-Executive Director of Ramsay Health Care, Ms Penrose also serves as a Director of Vicinity Centres, Bank of Queensland and Estia Health. Ms Penrose is a member of Chief Executive Women and on the Board of Marshall Investments Pty Limited and Rugby Australia Limited. She is a member of the Risk management committee.
|
Mr Steven Andrew Sargent | Non-Executive Director | Nov 2021 |
Mr Sargent has international executive experience including 22 years at General Electric where he led businesses across a range of industries including healthcare, energy and financial services across the USA, Europe and Asia. Mr Sargent has been serving as a non-executive director on several boards since 2015 and is currently a Non-Executive Director of Origin Energy Limited and Deputy Chairman and Lead Independent Director of infection prevention company Nanosonics Limited. He is also currently a Non-Executive Director and Chairman of OFX Group Limited. His unlisted board activities include Chairman of The Origin Energy Foundation Limited, Origin's philanthropic arm, and Non-Executive Director of The Great Barrier Reef Foundation.
|
Ms Claudia Ricarda Rita Sussmuth Dyckerhoff | Non-Executive Director | Oct 2018 |
Dr Dyckerhoff has global experience in hospitals and health care across Europe, Asia, and the USA. She joined McKinsey & Company in Switzerland in 1995 and was transferred to the USA focusing on supporting health care companies, including pharmaceutical/ medical device companies, payor, provider and health systems in Europe and the USA. In 2006, Dr Sussmuth Dyckerhoff transferred to China, was elected Senior Partner in 2010 and supported health care companies as well as governments across Asia. She also led McKinsey's Asia-wide Health Systems and Services Sector. Dr Dyckerhoff also supports start-ups in the health care area; she joined the board of the Health Tech company HUMA in April 2021 and the board of QuEST Global in November 2020. She is a member of the Risk management committee.
|
Mr James Malcolm McMurdo | Non-Executive Director | Sep 2019 |
Mr McMurdo has over 30 years finance and banking experience. He has a background in corporate advisory spanning across mergers and acquisitions, strategic advisory and financing with experience across multiple industries including the healthcare sector. He has held senior operating management roles and worked in both the Asia Pacific and European regions.Mr McMurdo is one of the Founding Partners of Privatus Capital Partners, an advisory and merchant banking business focussed on private capital. Prior to establishing Privatus, Mr McMurdo held senior management roles at Deutsche Bank and was based in Hong Kong. During his time at Deutsche Bank, he was Global Co-Head of Corporate Finance, Head of Corporate and Investment Bank for Asia Pacific and CEO for Australia and New Zealand. He sat on the firm's Global Executive Committee for the Corporate and Investment Bank for four years. Prior to this, Mr McMurdo was a Partner at Goldman Sachs, where he held senior positions in the Investment Banking Division in Australia and Europe.
|
Ms Henrietta Rowe | Company SecretaryGroup General Counsel | Jun 2019 |
-
|
Mr Martyn Roberts | Chief Financial Officer |
-
|
|
Dr Robert Herkes | Chief Medical Officer |
-
|
|
Henrietta Rowe | Company SecretaryGroup General Counsel |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 51,594,147 | 22.54% |
Paul Ramsay Holdings Pty Limited | 42,999,269 | 18.78% |
J P Morgan Nominees Australia Pty Limited | 30,788,535 | 13.45% |
Citicorp Nominees Pty Limited | 15,714,365 | 6.86% |
National Nominees Limited | 7,228,641 | 3.15% |
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 4,986,109 | 2.17% |
Woolwich Investments Pty Ltd <The Siddle Family Trust> | 3,750,000 | 1.63% |
BNP Paribas Noms Pty Ltd <Drp> | 2,943,857 | 1.28% |
Custodial Services Limited <Beneficiaries Holding A/C> | 2,759,174 | 1.20% |
Argo Investments Limited | 2,023,131 | 0.88% |
Cs Third Nominees Pty Limited < HSBC Cust Nom Au Ltd 13 A/C> | 1,949,041 | 0.85% |
Australian Foundation Investment Company Limited | 1,915,000 | 0.83% |
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> | 1,126,284 | 0.49% |
Certane CT Pty Ltd | 1,083,948 | 0.47% |
Netwealth Investments Limited <Wrap Services A/C> | 1,062,130 | 0.46% |
HSBC Custody Nominees (Australia) Limited (i) | 1,052,692 | 0.46% |
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd | 883,811 | 0.38% |
Mutual Trust Pty Ltd | 769,053 | 0.33% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 638,713 | 0.27% |
BNP Paribas Noms (Nz) Ltd <Drp> | 538,278 | 0.23% |